PRLD 8-K: Q2 2025 Results Furnished with Investor Deck

Rhea-AI Filing Summary

Prelude Therapeutics furnished a press release disclosing its financial results for the three months ended June 30, 2025, which is attached to this report as Exhibit 99.1. Management also prepared investor presentation materials intended for use in investor presentations and attached those materials as Exhibit 99.2. The filing notes an interactive data file is included as Exhibit 104.

The report emphasizes that the press release and presentation are being furnished, not filed, and therefore are not incorporated by reference into the company’s other securities filings. The 8-K itself does not include the underlying financial figures in its body; readers must review Exhibit 99.1 for the detailed results. The form is signed on the company’s behalf by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer.

Insights

Financial Analyst

TL;DR: The 8-K furnishes Q2 2025 results and a presentation but contains no financial line items itself, so immediate assessment requires reviewing the exhibits.

The filing communicates that a press release with quarterly results and an investor deck have been furnished as exhibits. Because the 8-K body does not present revenue, expense, cash, or guidance figures, this document alone does not change valuation models or metrics. The presence of an Inline XBRL cover (Exhibit 104) suggests machine-readable data accompanies the release, but the material financial details must be extracted from Exhibit 99.1 and the accompanying XBRL to evaluate operating performance and cash position.

Corporate Governance Expert

TL;DR: The company explicitly states the materials are "furnished, not filed," limiting their incorporation into other filings and clarifying legal treatment.

From a disclosure-compliance perspective, the filing follows standard practice by furnishing a press release and presentation and clarifying that those materials are not subject to Section 18 filing incorporation. That distinction reduces the risk that the exhibits become implicitly incorporated into future filings. The document records the included exhibits (99.1, 99.2, 104) and identifies the company officer who executed the report, consistent with reporting protocols. There is no indication in this filing of governance irregularities or material adverse events.

false000167866000016786602025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Prelude Therapeutics Incorporated

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39527				81-1384762
(State or other jurisdiction of incorporation or organization)		(Commission File Number)				(I.R.S. Employer Identification No.)
175 Innovation Boulevard Wilmington, Delaware				19805
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (302) 467-1280

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		PRLD		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Prelude Therapeutics Incorporated (the "Company") issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

The Company has prepared investor presentation materials with information about the Company, which it intends to use as part of investor presentations. A copy of the investor presentation materials to be used by management for presentations is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K and in Exhibits 99.1 and 99.2 attached hereto is being furnished, but shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press release issued by Prelude Therapeutics Incorporated regarding its financial results for the three months ended June 30, 2025, dated August 14, 2025.
99.2		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PRELUDE THERAPEUTICS INCORPORATED
Date: August 14, 2025	By:	/s/ Bryant Lim
		Bryant Lim
		Chief Legal Officer, Corporate Secretary, and Chief Financial Officer

FAQ

What did Prelude Therapeutics (PRLD) disclose in this 8-K?

Prelude furnished a press release announcing financial results for the three months ended June 30, 2025 (Exhibit 99.1) and an investor presentation for management use (Exhibit 99.2).

Are the press release and presentation "filed" or "furnished"?

The materials are furnished, not filed. The filing explicitly states the exhibits are being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act.

Does the 8-K include the company’s financial statements or figures?

No. The 8-K notifies readers that the press release contains the results but the body of this report does not present the financial figures; review Exhibit 99.1 for detailed results.

Which exhibits are included with this report?

Exhibit 99.1: Press release; Exhibit 99.2: Presentation; and Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Who signed the 8-K on behalf of Prelude Therapeutics (PRLD)?

Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer is the signatory identified in the filing.